Global X China Biotech Innovation ETF (DELISTED) (CHB:DL)
6.64
0.00 (0.00%)
USD |
NASDAQ |
Feb 21, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.65% | -1.19% | 1.412M | -- |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| -- | 31.98% | -456041.0 | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index ("underlying index"). The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Fixed Income Style | -- |
| Broad Asset Class | International Equity |
| Broad Category | Equity |
| Category Name | China Region |
| Category Index | MSCI China NR USD |
| Global Category Name | Greater China Equity |
| YCharts Categorization | China Equity |
| YCharts Benchmark | MSCI China Total Return (^MSCNTR) |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Global X Funds |
| Prospectus Benchmark Index | |
| Solactive China Biotech Inno NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSACXUSNTR | 100.0% |
| Manager Tenure | |
| Nam To | 3.36 yrs |
| Wayne Xie | 3.36 yrs |
| Vanessa Yang | 3.09 yrs |
| Sandy Lu | 1.84 yrs |
Performance Versus Category
Annual Total Returns Versus Peers
As of February 21, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index ("underlying index"). The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Fixed Income Style | -- |
| Broad Asset Class | International Equity |
| Broad Category | Equity |
| Category Name | China Region |
| Category Index | MSCI China NR USD |
| Global Category Name | Greater China Equity |
| YCharts Categorization | China Equity |
| YCharts Benchmark | MSCI China Total Return (^MSCNTR) |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Global X Funds |
| Prospectus Benchmark Index | |
| Solactive China Biotech Inno NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSACXUSNTR | 100.0% |
| Manager Tenure | |
| Nam To | 3.36 yrs |
| Wayne Xie | 3.36 yrs |
| Vanessa Yang | 3.09 yrs |
| Sandy Lu | 1.84 yrs |